Project Grant R01HL177581
Award Date 9/19/25
Completion Date 5/31/29
Dollars Obligated $774K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $161,903 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate risk stratification and outcomes across the spectrum of cardiovascular toxicities from immune checkpoint inhibitors (ICIs) for cancer therapy. The key products or services to be delivered include: Retrospective examination of cardiac and oncologic outcomes associated with ICI cardiotoxicity, stratified by patient symptoms and troponin-I...
- The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $131,211 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Leland Stanford Junior University. The award, effective from July 15, 2025 through June 30, 2027, supports research to track T cell differentiation and predict/control alloreactive disease in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients. The project aims to identify alloreactive T cell subsets that develop after allo-HSCT...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on advancing scientific understanding of the connections between cancer and cardiovascular disease. The $1,102,957 grant awarded to The Leland Stanford Junior University will fund a multidisciplinary research program spanning population genetics, cardio-oncology, and translational medicine. The key objectives are to precisely...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Leland Stanford Junior University. The award, with a performance period from August 1, 2025 to July 31, 2027, aims to enhance cell therapies for peripheral arterial disease using human-compatible protease-based controls. The project will develop synthetic biology strategies to enable the quantitative and dynamic regulation of growth factors and...
- This federal Project Grant award, valued at $425,505 and awarded on September 15, 2025, supports research conducted by Louisiana State University Health Sciences Center-Shreveport focused on the role of cell-specific programmed death-ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and cancer. The research, funded under the National Institutes of Health's Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the underlying mechanisms of immune-related...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $162,486 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University) to engineer hematopoietic stem cells to generate therapeutic antibody-secreting B cells as a potential treatment for hypercholesterolemia. The project aims to test the hypothesis that engineering hematopoietic stem and progenitor cells to produce B cells that secrete anti-PCSK9...
- The federal Project Grant award for "Deciphering Interactions Between Human T Cells and Cardiomyocytes in Immune Checkpoint Inhibitor-Related Myocarditis" was provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research). The $197,640.00 award, beginning on Aug 1, 2025, will support research conducted by Steven Blum, MD, an Instructor at Harvard Medical School and Assistant at Massachusetts General Hospital, to...
- This federal Project Grant award of $112,822 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of dendritic cell (DC) lysosome activity in immune checkpoint inhibitor (ICI)-associated myocarditis, a highly fatal disease of inflammation-induced cardiac injury. The two key goals are: To characterize differences in lysosomal activity between wild-type DCs and DCs deficient in the immune checkpoint receptor PD-1 (PD-1...